Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms AVAglio
- Sponsors Chugai Pharmaceutical; Roche
- 07 Jun 2022 Results of an analysis comparing survival outcome using patient-level data from clinical studies: NCT00943826, NCT00813943, NCT00689221 and real-world data from an institutional dataset at a large academic center presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results of factors predicting long-term survival (n=798) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results of retrospective post-hoc analysis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology